FSFernando Salgado-Polo

Fernando Salgado-Polo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fernando Salgado-Polo has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De novo macrocyclic peptide discovery produces potent class A GPCR ligands with diverse pharmacology

    by Fernando Salgado-Polo, Marin Matic, Philip Ben Rainsford, Felix Faas, Max Meyrath, Rajesh Regmi, Mette M Rosenkilde, Martyna Szpakowska, Andy Chevigné, Alexander S Hauser, et al.

    G protein-coupled receptors (GPCRs) represent one of the largest protein families of therapeutic importance, as over one third of all currently approved drugs target GPCRs. A growing proportion of GPCR drugs are peptides. However, class A GPCRs (over 80% of clinically studied targets) are underexploited as peptide targets, presumably since their only structured domain is the core, seven-helix, integral membrane fold presenting a limited solvent-exposed surface area. Screening libraries of de novo macrocyclic peptides have allowed for the targeting of otherwise intractable proteins, but their potential to generate selective ligands for class A GPCRs has not been demonstrated. Here, we used random nonstandard peptides integrated discovery (RaPID) to identify de novo macrocyclic peptide ligands targeting the chemokine receptor CXCR4. CXCR4 regulates cell migration, immune surveillance, and inflammation, making it an important therapeutic target for multiple diseases. We discovered novel, potent CXCR4-selective antagonists binding within the orthosteric pocket with nanomolar affinity. The most active peptides effectively inhibited receptor signaling, suppressed chemokine-driven cell migration, and blocked CXCR4-driven HIV entry. Our results show that even the structurally minimal class A GPCRs are viable targets for de novo cyclic peptide discovery, highlighting the potential for uncovering ligands towards other members of the GPCR superfamily.

  • Open Access

    Mechanisms of XCR1 Membrane Trafficking and Constitutive Endocytosis

    by Qiao Li, Fabian Pfersdorf, Fernando Salgado‐Polo, Martin Gustavsson

    Chemokines orchestrate immune cell trafficking through receptor‐mediated signalling and are implicated in inflammatory, autoimmune and neuropathic disorders. The XCL1–XCR1 axis is of particular interest because XCR1 is selectively expressed on mature conventional type 1 dendritic cells (cDC1s), where it supports communication with activated CD8 + T cells and NK cells and promotes antigen cross‐presentation. This selectivity has made XCR1 an attractive target for dendritic cell–based cancer vaccines, while emerging evidence also links XCL1–XCR1 signalling to neuroinflammation and pain. Despite its therapeutic potential, the mechanisms governing XCR1 activation and trafficking remain understudied. Here, we characterize XCR1 expression, membrane trafficking, and basal internalization to define mechanisms that may influence therapeutic targeting. We show that XCR1 undergoes constitutive internalization through a β‐arrestin–independent but adaptor protein 2 (AP2)–dependent pathway, distinguishing it from other chemokine receptors with constitutive endocytosis. Furthermore, we identify specific sequence motifs critical for its subcellular localization and intracellular trafficking. These findings provide new mechanistic insights into XCR1 regulation and may inform the development of targeted therapeutics and antigen‐delivery strategies in cancer and inflammation.

  • Open Access

    Chemokine receptor activity is differentially regulated by membrane cholesterol

    by Fernando Salgado-Polo, Jose Fernández-González, Carolina Ferrera-Mena, Suresh Subedi, Sriram Tiruvadi-Krishnan, Philip Ben Rainsford, Rajesh Regmi, Rajan Lamichhane, Martin Gustavsson

    Cholesterol is a key membrane component that regulates G protein-coupled receptor (GPCR) function, yet its molecular mechanisms remain unclear. Here, we combine chemical extraction of membrane sterols with functional signaling assays and single-molecule fluorescence resonance energy transfer (smFRET) to define how cholesterol controls activation of chemokine receptors. Reduction of membrane cholesterol in mammalian cells selectively decreased constitutive and agonist-induced signaling across CXCR1, CXCR2, CXCR4, while it activated ACKR3, and did not affect CXCR3, revealing receptor-specific dependence on membrane sterols. Mechanistically, cholesterol regulation partly required the conserved class A GPCR residue Trp 4 .50 and shifted agonist-bound CXCR4 toward active conformational states, providing a molecular explanation for its functional effects. In contrast, replenishment with oxidized cholesterol species failed to restore receptor activity, distinguishing cholesterol from oxysterols as modulators of receptor activation. Our findings identify cholesterol as an allosteric regulator of chemokine receptors and suggest that oxysterols may reshape inflammatory signaling by selectively modulating GPCR activity.


  • Open Access

    Basal Internalization and Subcellular Localization of XCR1

    by Qiao Li, Fabian Pfersdorf, Fernando Salgado-Polo, Martin Gustavsson

    Chemokines orchestrate immune cell trafficking through receptor-mediated signaling and are implicated in inflammatory, autoimmune, and neuropathic disorders. The XCL1–XCR1 axis is of particular interest because XCR1 is selectively expressed on mature conventional type 1 dendritic cells (cDC1s), where it supports communication with activated CD8+ T cells and NK cells and promotes antigen cross-presentation. This selectivity has made XCR1 an attractive target for dendritic cell–based cancer vaccines, while emerging evidence also links XCL1–XCR1 signaling to neuroinflammation and pain. Despite its therapeutic potential, the mechanisms governing XCR1 activation and trafficking remain understudied. Here, we characterize XCR1 expression, membrane trafficking, and basal internalization to define mechanisms that may influence therapeutic targeting. We show that XCR1 undergoes constitutive internalization through a β-arrestin-independent but adaptor protein 2 (AP2)-dependent pathway, distinguishing it from other chemokine receptors with constitutive endocytosis. Furthermore, we identify specific sequence motifs critical for its subcellular localization and intracellular trafficking. These findings provide new mechanistic insights into XCR1 regulation and may inform the development of targeted therapeutics and antigen-delivery strategies in cancer and inflammation.

  • Open Access

    Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells

    by Elisa Matas-Rico, Elselien Frijlink, Irene van der Haar Àvila, Apostolos Menegakis, Maaike van Zon, Andrew J. Morris, Jan Koster, Fernando Salgado-Polo, Sander de Kivit, Telma Lança, et al.


  • A novel mechanism of autotaxin-mediated cell signaling that is independent of catalytic activity and inhibited by ziritaxestat

    by Fernando Salgado-Polo, Razvan Borza, Paul Ford, Bertrand Heckmann, Anastassis Perrakis

    Autotaxin (ATX/ENPP2) has attracted widespread attention as a target for various pathologies, notably idiopathic pulmonary fibrosis (IPF). ATX is predominantly (~90%) responsible for the extracellular production of the signaling molecule lysophosphatidic acid (LPA), which acts through two specific families of G protein-coupled receptors. We show that ATX, even when catalytically inactive, is more potent than LPA alone in inducing downstream signaling events in cells. While catalytic activity is dispensable for ATX-mediated signaling, the allosteric tunnel of ATX is necessary to mediate this effect. Notably, this signal is transmitted through Edg family (LPA1-3) but not non-Edg family (LPA4-6) LPA receptors, and is affected by the presence of α5β1 integrin (Fig). Crucially, while orthosteric type I ATX inhibitors do not abrogate ATX-mediated signaling, hybrid (orthosteric-allosteric) type IV ATX inhibitors that occupy the ATX tunnel do. Finally, this correlates with previous results (Heckmann B, et al. ATS 2019; poster A108), where ziritaxestat, but not Cpd A, inhibited bleomycin-induced lung fibrosis in mice. In conclusion, we describe a new, unexpected and unique direct ATX signaling mechanism. Both catalytic production and presentation of bioactive LPA are necessary for biological activity, explaining the predicted clinical benefit of ziritaxestat in treating IPF. Funding: Galapagos

  • Open Access

    LAHMA: structure analysis through local annotation of homology-matched amino acids

    by Bart van Beusekom, George Damaskos, Maarten L. Hekkelman, Fernando Salgado-Polo, Yoshitaka Hiruma, Anastassis Perrakis, Robbie P. Joosten

    Comparison of homologous structure models is a key step in analyzing protein structure. With a wealth of homologous structures, comparison becomes a tedious process, and often only a small (user-biased) selection of data is used. A multitude of structural superposition algorithms are then typically used to visualize the structures together in 3D and to compare them. Here, the Local Annotation of Homology-Matched Amino acids (LAHMA) website (https://lahma.pdb-redo.eu) is presented, which compares any structure model with all of its close homologs from the PDB-REDO databank. LAHMA displays structural features in sequence space, allowing users to uncover differences between homologous structure models that can be analyzed for their relevance to chemistry or biology. LAHMA visualizes numerous structural features, also allowing one-click comparison of structure-quality plots (for example the Ramachandran plot) and `in-browser' structural visualization of 3D models.


  • Open Access

    Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8 + T cells

    by Elisa Matas-Rico, Elselien Frijlink, Irene van der Haar Àvila, Apostolos Menegakis, Maaike van Zon, Andrew J. Morris, Jan Koster, Fernando Salgado-Polo, Sander de Kivit, Telma Lança, et al.

    Summary: Autotaxin (ATX) is secreted by diverse cell types to produce lysophosphatidic acid (LPA) that regulates multiple biological functions via G protein-coupled receptors LPAR1-6. ATX/LPA promotes tumor cell migration and metastasis mainly via LPAR1; however, its actions in the tumor immune microenvironment remain unclear. Here, we show that ATX secreted by melanoma cells is chemorepulsive for tumor-infiltrating lymphocytes and circulating CD8 + T cells ex vivo , with ATX functioning as an LPA-producing chaperone. Mechanistically, T-cell repulsion predominantly involves G α 12/13 -coupled LPAR6. Upon anti-cancer vaccination of tumor-bearing mice, ATX does not affect the induction of systemic T-cell responses but suppresses tumor infiltration of cytotoxic CD8 + T cells and thereby impairs tumor regression. Moreover, single-cell data from patient samples are consistent with intra-tumor ATX acting as a T-cell repellent. These studies highlight an unexpected role for the pro-metastatic ATX-LPAR axis in suppressing CD8 + T-cell infiltration to impede anti-tumor immunity, suggesting new therapeutic opportunities.


  • Open Access

    Sequence-dependent trafficking and activity of GDE2, a GPI-specific phospholipase promoting neuronal differentiation

    by Fernando Salgado-Polo, Michiel van Veen, Bram van Den Broek, Kees Jalink, Daniela Leyton-Puig, Anastassis Perrakis, Wouter H. Moolenaar, Elisa Matas-Rico

    GDE2 (also known as GDPD5) is a multispanning membrane phosphodiesterase with phospholipase D-like activity that cleaves select glycosylphosphatidylinositol (GPI)-anchored proteins and thereby promotes neuronal differentiation both in vitro and in vivo. GDE2 is a prognostic marker in neuroblastoma, while loss of GDE2 leads to progressive neurodegeneration in mice; however, its regulation remains unclear. Here, we report that, in immature neuronal cells, GDE2 undergoes constitutive endocytosis and travels back along both fast and slow recycling routes. GDE2 trafficking is directed by C-terminal tail sequences that determine the ability of GDE2 to cleave GPI-anchored glypican-6 (GPC6) and induce a neuronal differentiation program. Specifically, we define a GDE2 truncation mutant that shows aberrant recycling and is dysfunctional, whereas a consecutive deletion results in cell-surface retention and gain of GDE2 function, thus uncovering distinctive regulatory sequences. Moreover, we identify a C-terminal leucine residue in a unique motif that is essential for GDE2 internalization. These findings establish a mechanistic link between GDE2 neuronal function and sequence-dependent trafficking, a crucial process gone awry in neurodegenerative diseases. This article has an associated First Person interview with the first author of the paper.


  • Open Access

    The Structural Binding Mode of the Four Autotaxin Inhibitor Types that Differentially Affect Catalytic and Non-Catalytic Functions

    by Fernando Salgado-Polo, Anastassis Perrakis

    Autotaxin (ATX) is a secreted lysophospholipase D, catalysing the conversion of lysophosphatidylcholine (LPC) to bioactive lysophosphatidic acid (LPA). LPA acts through two families of G protein-coupled receptors (GPCRs) controlling key cellular responses, and it is implicated in many physiological processes and pathologies. ATX, therefore, has been established as an important drug target in the pharmaceutical industry. Structural and biochemical studies of ATX have shown that it has a bimetallic nucleophilic catalytic site, a substrate-binding (orthosteric) hydrophobic pocket that accommodates the lipid alkyl chain, and an allosteric tunnel that can accommodate various steroids and LPA. In this review, first, we revisit what is known about ATX-mediated catalysis, crucially in light of allosteric regulation. Then, we present the known ATX catalysis-independent functions, including binding to cell surface integrins and proteoglycans. Next, we analyse all crystal structures of ATX bound to inhibitors and present them based on the four inhibitor types that are established based on the binding to the orthosteric and/or the allosteric site. Finally, in light of these data we discuss how mechanistic differences might differentially modulate the activity of the ATX-LPA signalling axis, and clinical applications including cancer.